Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV
Reliable non-invasive methods for the evaluation of liver fibrosis are desirable, and the risk factors associated with fibrosis are not fully identified. A cross-sectional study of a cohort of 805 HIV-HCV-coinfected patients with active HCV replication, most (95.2%) of whom were intravenous drug use...
Gespeichert in:
Veröffentlicht in: | Antiviral therapy 2011, Vol.16 (1), p.27-35 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 35 |
---|---|
container_issue | 1 |
container_start_page | 27 |
container_title | Antiviral therapy |
container_volume | 16 |
creator | CARTON, José A COLLAZOS, Julio DE LA FUENTE, Belén LUISA GARCIA-ALCALDE, Maria SUAREZ-ZARRACINA, Tomas RODRIGUEZ-GUARDADO, Azucena ASENSI, Victor |
description | Reliable non-invasive methods for the evaluation of liver fibrosis are desirable, and the risk factors associated with fibrosis are not fully identified.
A cross-sectional study of a cohort of 805 HIV-HCV-coinfected patients with active HCV replication, most (95.2%) of whom were intravenous drug users, was conducted. Liver fibrosis was measured by transient elastometry with cutoff values of 7.2 kPa (significant fibrosis), 9.4 kPa (advanced fibrosis) and 14.0 kPa (cirrhosis), and by liver fibrosis indexes (LFI; APRI, Forns and FIB-4). Available liver biopsies were also evaluated.
The prevalences of significant fibrosis, advanced fibrosis and cirrhosis were 55.8%, 38.4% and 23.5%, respectively. A number of parameters were associated both in the univariate and multivariate analyses with each of the diverse fibrosis groups; however, only six of them were predictive of all stages of fibrosis: heavy alcohol intake (odds ratio [OR] 3.37, 95% confidence interval [CI] 2.02-5.59; P < 0.001), duration of HCV infection (OR 1.13, 95% CI 1.07-1.19; P < 0.001), CDC category C3 (OR 1.80, 95% CI 1.07-3.02; P=0.026), anti-HCV treatment failure (OR 4.37, 95% CI 2.24-8.55; P < 0.001), thrombocytopaenia (OR 1.015, 95% CI 1.011-1.019; P < 0.001) and increased aspartate aminotransferase (1.006, 95% CI 1.0021-1.010; P = 0.004). Furthermore, 53%, 68% and 80% of patients with significant fibrosis, advanced fibrosis and cirrhosis, respectively, had increased measures on at least one of the LFI, with the Forns index being the most sensitive. Area under the receiver operating characteristic curves of elastometry to predict histological fibrosis was 0.83 (95% CI 0.76-0.90), 0.89 (95% CI 0.83-0.95) and 0.87 (95% CI 0.80-0.94) for Metavir score ≥ F2, ≥ F3 and F4, respectively.
Elastometry constitutes a useful tool in the diagnosis and follow-up of HIV-HCV-coinfected patients. Fibrosis is associated with diverse factors, some of them treatable or preventable, which need to be addressed considering the high prevalence and course of fibrosis in these patients. |
doi_str_mv | 10.3851/IMP1708 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_858421281</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>851476524</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-875428657231aa1c88f9b19a47660cc752f7401d276c4b91adcd4ea2eea754783</originalsourceid><addsrcrecordid>eNqNkE1Lw0AQhhdRbK3iP5C9iKfozn4km6MUawsVPWhPQphsNrqSJnU3qfjvjRjrVRiYy_O-MzyEnAK7FFrB1eLuARKm98iYM8kizpTeJ2MQKo1iJdSIHIXwxhjXKWOHZMRBAACLx-R5hqZtfKAYQmMctragH659pZXbWk9Ll_smuEBd3U_rcWvrpgu08N0L7YLtg6ZxdWnNLjhfrCjWBZ1PV8fkoMQq2JNhT8jT7OZxOo-W97eL6fUyMkLyNtKJklzHKuECEMFoXaY5pCiTOGbGJIqXiWRQ8CQ2Mk8BC1NIi9xa7JOJFhNy8dO78c17Z0ObrV0wtqqwtv23mVZacuAa_kFCf1Vx-UeaXkDwtsw23q3Rf2bAsm_n2eC8J8-Gzi5f22LH_UrugfMBwGCwKj3WxoU_TqRSc67EF5h9h18</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>851476524</pqid></control><display><type>article</type><title>Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>CARTON, José A ; COLLAZOS, Julio ; DE LA FUENTE, Belén ; LUISA GARCIA-ALCALDE, Maria ; SUAREZ-ZARRACINA, Tomas ; RODRIGUEZ-GUARDADO, Azucena ; ASENSI, Victor</creator><creatorcontrib>CARTON, José A ; COLLAZOS, Julio ; DE LA FUENTE, Belén ; LUISA GARCIA-ALCALDE, Maria ; SUAREZ-ZARRACINA, Tomas ; RODRIGUEZ-GUARDADO, Azucena ; ASENSI, Victor</creatorcontrib><description>Reliable non-invasive methods for the evaluation of liver fibrosis are desirable, and the risk factors associated with fibrosis are not fully identified.
A cross-sectional study of a cohort of 805 HIV-HCV-coinfected patients with active HCV replication, most (95.2%) of whom were intravenous drug users, was conducted. Liver fibrosis was measured by transient elastometry with cutoff values of 7.2 kPa (significant fibrosis), 9.4 kPa (advanced fibrosis) and 14.0 kPa (cirrhosis), and by liver fibrosis indexes (LFI; APRI, Forns and FIB-4). Available liver biopsies were also evaluated.
The prevalences of significant fibrosis, advanced fibrosis and cirrhosis were 55.8%, 38.4% and 23.5%, respectively. A number of parameters were associated both in the univariate and multivariate analyses with each of the diverse fibrosis groups; however, only six of them were predictive of all stages of fibrosis: heavy alcohol intake (odds ratio [OR] 3.37, 95% confidence interval [CI] 2.02-5.59; P < 0.001), duration of HCV infection (OR 1.13, 95% CI 1.07-1.19; P < 0.001), CDC category C3 (OR 1.80, 95% CI 1.07-3.02; P=0.026), anti-HCV treatment failure (OR 4.37, 95% CI 2.24-8.55; P < 0.001), thrombocytopaenia (OR 1.015, 95% CI 1.011-1.019; P < 0.001) and increased aspartate aminotransferase (1.006, 95% CI 1.0021-1.010; P = 0.004). Furthermore, 53%, 68% and 80% of patients with significant fibrosis, advanced fibrosis and cirrhosis, respectively, had increased measures on at least one of the LFI, with the Forns index being the most sensitive. Area under the receiver operating characteristic curves of elastometry to predict histological fibrosis was 0.83 (95% CI 0.76-0.90), 0.89 (95% CI 0.83-0.95) and 0.87 (95% CI 0.80-0.94) for Metavir score ≥ F2, ≥ F3 and F4, respectively.
Elastometry constitutes a useful tool in the diagnosis and follow-up of HIV-HCV-coinfected patients. Fibrosis is associated with diverse factors, some of them treatable or preventable, which need to be addressed considering the high prevalence and course of fibrosis in these patients.</description><identifier>ISSN: 1359-6535</identifier><identifier>EISSN: 2040-2058</identifier><identifier>DOI: 10.3851/IMP1708</identifier><identifier>PMID: 21311106</identifier><language>eng</language><publisher>London: International Medical Press</publisher><subject>Addictive behaviors ; Adult ; Adult and adolescent clinical studies ; Alcoholism - complications ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Area Under Curve ; Aspartate Aminotransferases - analysis ; Biological and medical sciences ; Cohort Studies ; Cross-Sectional Studies ; Drug addiction ; Drug Users ; Female ; Fibrosis - diagnosis ; Fibrosis - epidemiology ; Fibrosis - etiology ; Fibrosis - pathology ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepacivirus ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - pathology ; HIV ; HIV Infections - complications ; HIV Infections - drug therapy ; HIV Infections - pathology ; Human immunodeficiency virus ; Human viral diseases ; Humans ; Infectious diseases ; Liver Cirrhosis - diagnosis ; Liver Cirrhosis - epidemiology ; Liver Cirrhosis - etiology ; Liver Cirrhosis - pathology ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; Middle Aged ; Other diseases. Semiology ; Pharmacology. Drug treatments ; Prevalence ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Risk Factors ; Severity of Illness Index ; Substance Abuse, Intravenous - complications ; Thrombocytopenia - complications ; Treatment Failure ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids</subject><ispartof>Antiviral therapy, 2011, Vol.16 (1), p.27-35</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-875428657231aa1c88f9b19a47660cc752f7401d276c4b91adcd4ea2eea754783</citedby><cites>FETCH-LOGICAL-c342t-875428657231aa1c88f9b19a47660cc752f7401d276c4b91adcd4ea2eea754783</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,4012,27910,27911,27912</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23948225$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21311106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>CARTON, José A</creatorcontrib><creatorcontrib>COLLAZOS, Julio</creatorcontrib><creatorcontrib>DE LA FUENTE, Belén</creatorcontrib><creatorcontrib>LUISA GARCIA-ALCALDE, Maria</creatorcontrib><creatorcontrib>SUAREZ-ZARRACINA, Tomas</creatorcontrib><creatorcontrib>RODRIGUEZ-GUARDADO, Azucena</creatorcontrib><creatorcontrib>ASENSI, Victor</creatorcontrib><title>Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV</title><title>Antiviral therapy</title><addtitle>Antivir Ther</addtitle><description>Reliable non-invasive methods for the evaluation of liver fibrosis are desirable, and the risk factors associated with fibrosis are not fully identified.
A cross-sectional study of a cohort of 805 HIV-HCV-coinfected patients with active HCV replication, most (95.2%) of whom were intravenous drug users, was conducted. Liver fibrosis was measured by transient elastometry with cutoff values of 7.2 kPa (significant fibrosis), 9.4 kPa (advanced fibrosis) and 14.0 kPa (cirrhosis), and by liver fibrosis indexes (LFI; APRI, Forns and FIB-4). Available liver biopsies were also evaluated.
The prevalences of significant fibrosis, advanced fibrosis and cirrhosis were 55.8%, 38.4% and 23.5%, respectively. A number of parameters were associated both in the univariate and multivariate analyses with each of the diverse fibrosis groups; however, only six of them were predictive of all stages of fibrosis: heavy alcohol intake (odds ratio [OR] 3.37, 95% confidence interval [CI] 2.02-5.59; P < 0.001), duration of HCV infection (OR 1.13, 95% CI 1.07-1.19; P < 0.001), CDC category C3 (OR 1.80, 95% CI 1.07-3.02; P=0.026), anti-HCV treatment failure (OR 4.37, 95% CI 2.24-8.55; P < 0.001), thrombocytopaenia (OR 1.015, 95% CI 1.011-1.019; P < 0.001) and increased aspartate aminotransferase (1.006, 95% CI 1.0021-1.010; P = 0.004). Furthermore, 53%, 68% and 80% of patients with significant fibrosis, advanced fibrosis and cirrhosis, respectively, had increased measures on at least one of the LFI, with the Forns index being the most sensitive. Area under the receiver operating characteristic curves of elastometry to predict histological fibrosis was 0.83 (95% CI 0.76-0.90), 0.89 (95% CI 0.83-0.95) and 0.87 (95% CI 0.80-0.94) for Metavir score ≥ F2, ≥ F3 and F4, respectively.
Elastometry constitutes a useful tool in the diagnosis and follow-up of HIV-HCV-coinfected patients. Fibrosis is associated with diverse factors, some of them treatable or preventable, which need to be addressed considering the high prevalence and course of fibrosis in these patients.</description><subject>Addictive behaviors</subject><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Alcoholism - complications</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>Area Under Curve</subject><subject>Aspartate Aminotransferases - analysis</subject><subject>Biological and medical sciences</subject><subject>Cohort Studies</subject><subject>Cross-Sectional Studies</subject><subject>Drug addiction</subject><subject>Drug Users</subject><subject>Female</subject><subject>Fibrosis - diagnosis</subject><subject>Fibrosis - epidemiology</subject><subject>Fibrosis - etiology</subject><subject>Fibrosis - pathology</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepacivirus</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - pathology</subject><subject>HIV</subject><subject>HIV Infections - complications</subject><subject>HIV Infections - drug therapy</subject><subject>HIV Infections - pathology</subject><subject>Human immunodeficiency virus</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Liver Cirrhosis - diagnosis</subject><subject>Liver Cirrhosis - epidemiology</subject><subject>Liver Cirrhosis - etiology</subject><subject>Liver Cirrhosis - pathology</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Other diseases. Semiology</subject><subject>Pharmacology. Drug treatments</subject><subject>Prevalence</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Risk Factors</subject><subject>Severity of Illness Index</subject><subject>Substance Abuse, Intravenous - complications</subject><subject>Thrombocytopenia - complications</subject><subject>Treatment Failure</subject><subject>Viral diseases</subject><subject>Viral diseases of the lymphoid tissue and the blood. Aids</subject><issn>1359-6535</issn><issn>2040-2058</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE1Lw0AQhhdRbK3iP5C9iKfozn4km6MUawsVPWhPQphsNrqSJnU3qfjvjRjrVRiYy_O-MzyEnAK7FFrB1eLuARKm98iYM8kizpTeJ2MQKo1iJdSIHIXwxhjXKWOHZMRBAACLx-R5hqZtfKAYQmMctragH659pZXbWk9Ll_smuEBd3U_rcWvrpgu08N0L7YLtg6ZxdWnNLjhfrCjWBZ1PV8fkoMQq2JNhT8jT7OZxOo-W97eL6fUyMkLyNtKJklzHKuECEMFoXaY5pCiTOGbGJIqXiWRQ8CQ2Mk8BC1NIi9xa7JOJFhNy8dO78c17Z0ObrV0wtqqwtv23mVZacuAa_kFCf1Vx-UeaXkDwtsw23q3Rf2bAsm_n2eC8J8-Gzi5f22LH_UrugfMBwGCwKj3WxoU_TqRSc67EF5h9h18</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>CARTON, José A</creator><creator>COLLAZOS, Julio</creator><creator>DE LA FUENTE, Belén</creator><creator>LUISA GARCIA-ALCALDE, Maria</creator><creator>SUAREZ-ZARRACINA, Tomas</creator><creator>RODRIGUEZ-GUARDADO, Azucena</creator><creator>ASENSI, Victor</creator><general>International Medical Press</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>2011</creationdate><title>Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV</title><author>CARTON, José A ; COLLAZOS, Julio ; DE LA FUENTE, Belén ; LUISA GARCIA-ALCALDE, Maria ; SUAREZ-ZARRACINA, Tomas ; RODRIGUEZ-GUARDADO, Azucena ; ASENSI, Victor</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-875428657231aa1c88f9b19a47660cc752f7401d276c4b91adcd4ea2eea754783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Addictive behaviors</topic><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Alcoholism - complications</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>Area Under Curve</topic><topic>Aspartate Aminotransferases - analysis</topic><topic>Biological and medical sciences</topic><topic>Cohort Studies</topic><topic>Cross-Sectional Studies</topic><topic>Drug addiction</topic><topic>Drug Users</topic><topic>Female</topic><topic>Fibrosis - diagnosis</topic><topic>Fibrosis - epidemiology</topic><topic>Fibrosis - etiology</topic><topic>Fibrosis - pathology</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepacivirus</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - pathology</topic><topic>HIV</topic><topic>HIV Infections - complications</topic><topic>HIV Infections - drug therapy</topic><topic>HIV Infections - pathology</topic><topic>Human immunodeficiency virus</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Liver Cirrhosis - diagnosis</topic><topic>Liver Cirrhosis - epidemiology</topic><topic>Liver Cirrhosis - etiology</topic><topic>Liver Cirrhosis - pathology</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Other diseases. Semiology</topic><topic>Pharmacology. Drug treatments</topic><topic>Prevalence</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Risk Factors</topic><topic>Severity of Illness Index</topic><topic>Substance Abuse, Intravenous - complications</topic><topic>Thrombocytopenia - complications</topic><topic>Treatment Failure</topic><topic>Viral diseases</topic><topic>Viral diseases of the lymphoid tissue and the blood. Aids</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>CARTON, José A</creatorcontrib><creatorcontrib>COLLAZOS, Julio</creatorcontrib><creatorcontrib>DE LA FUENTE, Belén</creatorcontrib><creatorcontrib>LUISA GARCIA-ALCALDE, Maria</creatorcontrib><creatorcontrib>SUAREZ-ZARRACINA, Tomas</creatorcontrib><creatorcontrib>RODRIGUEZ-GUARDADO, Azucena</creatorcontrib><creatorcontrib>ASENSI, Victor</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Antiviral therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>CARTON, José A</au><au>COLLAZOS, Julio</au><au>DE LA FUENTE, Belén</au><au>LUISA GARCIA-ALCALDE, Maria</au><au>SUAREZ-ZARRACINA, Tomas</au><au>RODRIGUEZ-GUARDADO, Azucena</au><au>ASENSI, Victor</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV</atitle><jtitle>Antiviral therapy</jtitle><addtitle>Antivir Ther</addtitle><date>2011</date><risdate>2011</risdate><volume>16</volume><issue>1</issue><spage>27</spage><epage>35</epage><pages>27-35</pages><issn>1359-6535</issn><eissn>2040-2058</eissn><abstract>Reliable non-invasive methods for the evaluation of liver fibrosis are desirable, and the risk factors associated with fibrosis are not fully identified.
A cross-sectional study of a cohort of 805 HIV-HCV-coinfected patients with active HCV replication, most (95.2%) of whom were intravenous drug users, was conducted. Liver fibrosis was measured by transient elastometry with cutoff values of 7.2 kPa (significant fibrosis), 9.4 kPa (advanced fibrosis) and 14.0 kPa (cirrhosis), and by liver fibrosis indexes (LFI; APRI, Forns and FIB-4). Available liver biopsies were also evaluated.
The prevalences of significant fibrosis, advanced fibrosis and cirrhosis were 55.8%, 38.4% and 23.5%, respectively. A number of parameters were associated both in the univariate and multivariate analyses with each of the diverse fibrosis groups; however, only six of them were predictive of all stages of fibrosis: heavy alcohol intake (odds ratio [OR] 3.37, 95% confidence interval [CI] 2.02-5.59; P < 0.001), duration of HCV infection (OR 1.13, 95% CI 1.07-1.19; P < 0.001), CDC category C3 (OR 1.80, 95% CI 1.07-3.02; P=0.026), anti-HCV treatment failure (OR 4.37, 95% CI 2.24-8.55; P < 0.001), thrombocytopaenia (OR 1.015, 95% CI 1.011-1.019; P < 0.001) and increased aspartate aminotransferase (1.006, 95% CI 1.0021-1.010; P = 0.004). Furthermore, 53%, 68% and 80% of patients with significant fibrosis, advanced fibrosis and cirrhosis, respectively, had increased measures on at least one of the LFI, with the Forns index being the most sensitive. Area under the receiver operating characteristic curves of elastometry to predict histological fibrosis was 0.83 (95% CI 0.76-0.90), 0.89 (95% CI 0.83-0.95) and 0.87 (95% CI 0.80-0.94) for Metavir score ≥ F2, ≥ F3 and F4, respectively.
Elastometry constitutes a useful tool in the diagnosis and follow-up of HIV-HCV-coinfected patients. Fibrosis is associated with diverse factors, some of them treatable or preventable, which need to be addressed considering the high prevalence and course of fibrosis in these patients.</abstract><cop>London</cop><pub>International Medical Press</pub><pmid>21311106</pmid><doi>10.3851/IMP1708</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1359-6535 |
ispartof | Antiviral therapy, 2011, Vol.16 (1), p.27-35 |
issn | 1359-6535 2040-2058 |
language | eng |
recordid | cdi_proquest_miscellaneous_858421281 |
source | MEDLINE; Sage Journals GOLD Open Access 2024; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
subjects | Addictive behaviors Adult Adult and adolescent clinical studies Alcoholism - complications Antibiotics. Antiinfectious agents. Antiparasitic agents Antiviral agents Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Area Under Curve Aspartate Aminotransferases - analysis Biological and medical sciences Cohort Studies Cross-Sectional Studies Drug addiction Drug Users Female Fibrosis - diagnosis Fibrosis - epidemiology Fibrosis - etiology Fibrosis - pathology Gastroenterology. Liver. Pancreas. Abdomen Hepacivirus Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - pathology HIV HIV Infections - complications HIV Infections - drug therapy HIV Infections - pathology Human immunodeficiency virus Human viral diseases Humans Infectious diseases Liver Cirrhosis - diagnosis Liver Cirrhosis - epidemiology Liver Cirrhosis - etiology Liver Cirrhosis - pathology Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences Middle Aged Other diseases. Semiology Pharmacology. Drug treatments Prevalence Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Risk Factors Severity of Illness Index Substance Abuse, Intravenous - complications Thrombocytopenia - complications Treatment Failure Viral diseases Viral diseases of the lymphoid tissue and the blood. Aids |
title | Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T13%3A01%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20associated%20with%20liver%20fibrosis%20in%20intravenous%20drug%20users%20coinfected%20with%20HIV%20and%20HCV&rft.jtitle=Antiviral%20therapy&rft.au=CARTON,%20Jos%C3%A9%20A&rft.date=2011&rft.volume=16&rft.issue=1&rft.spage=27&rft.epage=35&rft.pages=27-35&rft.issn=1359-6535&rft.eissn=2040-2058&rft_id=info:doi/10.3851/IMP1708&rft_dat=%3Cproquest_cross%3E851476524%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=851476524&rft_id=info:pmid/21311106&rfr_iscdi=true |